Status and phase
Conditions
Treatments
About
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
428 participants in 2 patient groups
Loading...
Central trial contact
Sa Xiao, PHD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal